Marina Biotech is a powerful partner for pharmaceutical and biotechnology companies, academic institutions, and research foundations who are interested in nucleic acid-based therapeutics and their potential for providing safe and effective treatment for a wide variety of diseases.
We place a high value on relationships that will provide us the opportunity to expand our internal research and development programs through access to new technologies and therapeutic programs. We actively seek alliances that will enhance our capabilities to deliver breakthrough therapeutics to improve people's lives.
Working closely with biotechnology and pharmaceutical companies, we can accelerate product opportunities that will ultimately benefit patients and partners alike. Our capabilities in nucleic acid drug discovery and our strong IP position provide partners with the ability to rapidly move nucleic acid-based product candidates through the R&D process.
Rosetta Genomics, Ltd.
Marina Biotech and Rosetta Genomics (NASDAQ: ROSG), a leading developer and provider of microRNA-based molecular diagnostics and therapeutics established a strategic alliance where the companies will collaborate to identify and develop microRNA-based products designed to diagnose and treat various neuromuscular diseases and dystrophies. The companies’ initial efforts are expected to be focused on myotonic dystrophy and Duchenne muscular dystrophy. Rosetta will apply its industry leading microRNA discovery expertise for the identification of microRNAs involved in the various dystrophy diseases. If the microRNA is determined to be correlative to the disease, Rosetta may further develop the microRNA into a diagnostic for patient identification and stratification. If the microRNA is determined to be involved in the disease pathology and represents a potential therapeutic target, Marina Biotech may develop the resulting microRNA-based therapeutic for clinical development.
Nitto Denko Avecia, Inc.
Marina Biotech and Nitto Avecia (formerly Girindus), a drug development and manufacturing services company and part of Nitto Denko, Inc., Japan’s leading diversified materials manufacturer, established a strategic alliance where Nitto Avecia will have exclusive rights to develop, supply and commercialize certain oligonucleotide constructs using Marina Biotech’s Conformationally Restricted Nucleotide (CRN) chemistry and in return, Marina Biotech will receive royalties from the sale of CRN-based oligonucleotide reagents as well as a robust supply of cGMP material for Marina Biotech and its partners’ pre-clinical, clinical, and commercialization needs.
ProNAi Therapeutics, Inc.
Marina Biotech and ProNAi, a privately-held biotechnology company pioneering DNA interference (DNAi) therapies for cancer, established an exclusive license agreement regarding the development and commercialization of DNAi-based therapeutics utilizing Marina Biotech’s novel SMARTICLES® liposomal delivery technology. ProNAi will have full responsibility for the development and commercialization of any products arising under the Agreement. Under terms of the Agreement, Marina Biotech could receive up to $14 million for each gene target in total upfront, clinical, and commercialization milestone payments, as well as royalties on sales, with ProNAi having the option to select any number of additional gene targets.
Mirna Therapeutics, Inc.
Marina Biotech and Mirna, a privately-held biotechnology company pioneering microRNA (miRNA) replacement therapy for cancer, established a license agreement regarding the development and commercialization of microRNA-based therapeutics utilizing Mirna’s proprietary microRNAs and Marina Biotech’s novel SMARTICLES liposomal delivery technology. Mirna will have full responsibility for the development and commercialization of any products arising under the Agreement, and Marina Biotech will support pre-clinical and process development efforts. Under terms of the Agreement, Marina Biotech could receive up to $63 million in total upfront, clinical, and commercialization milestone payments, as well as royalties on sales, based on the successful outcome of the collaboration.